share_log

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K：重大事件
美股sec公告 ·  04/26 16:45
Moomoo AI 已提取核心訊息
On April 25, 2024, Avenue Therapeutics, Inc., a specialty pharmaceutical company, filed an amendment to its certificate of incorporation to effectuate a 1-for-75 reverse stock split of its common stock. This action was approved by the company's stockholders following a definitive information statement filed with the SEC on March 18, 2024. The board of directors had previously determined the reverse stock split ratio on April 10, 2024. The reverse stock split, which was implemented to comply with Nasdaq's minimum bid price requirement, reduced the number of outstanding shares from approximately 44.7 million to about 0.6 million, adjusting for fractional shares. The split became effective on April 26, 2024, with the common stock trading on a post-split basis from the opening of business on that date. The company's common stock retained its ticker symbol 'ATXI' and was assigned a new CUSIP number. Avenue Therapeutics also announced the reverse stock split in a press release on April 24, 2024.
On April 25, 2024, Avenue Therapeutics, Inc., a specialty pharmaceutical company, filed an amendment to its certificate of incorporation to effectuate a 1-for-75 reverse stock split of its common stock. This action was approved by the company's stockholders following a definitive information statement filed with the SEC on March 18, 2024. The board of directors had previously determined the reverse stock split ratio on April 10, 2024. The reverse stock split, which was implemented to comply with Nasdaq's minimum bid price requirement, reduced the number of outstanding shares from approximately 44.7 million to about 0.6 million, adjusting for fractional shares. The split became effective on April 26, 2024, with the common stock trading on a post-split basis from the opening of business on that date. The company's common stock retained its ticker symbol 'ATXI' and was assigned a new CUSIP number. Avenue Therapeutics also announced the reverse stock split in a press release on April 24, 2024.
2024年4月25日，專業製藥公司Avenue Therapeutics, Inc. 提交了公司註冊證書修正案，以1比75的比例對其普通股進行反向分割。在2024年3月18日向美國證券交易委員會提交最終信息聲明後，該行動獲得了公司股東的批准。董事會此前已在 2024 年 4 月 10 日確定了反向股票拆分比率。反向股票拆分是爲了遵守納斯達克的最低出價要求而實施的，經零星股票調整後，已發行股票的數量從約4,470萬股減少到約60萬股。拆分於2024年4月26日生效，普通股自該日開業之日起在拆分後的基礎上交易。該公司的普通股保留了其股票代碼 “ATXI”，並被分配了新的CUSIP編號。Avenue Therapeutics還在2024年4月24日的新聞稿中宣佈了反向股票拆分。
2024年4月25日，專業製藥公司Avenue Therapeutics, Inc. 提交了公司註冊證書修正案，以1比75的比例對其普通股進行反向分割。在2024年3月18日向美國證券交易委員會提交最終信息聲明後，該行動獲得了公司股東的批准。董事會此前已在 2024 年 4 月 10 日確定了反向股票拆分比率。反向股票拆分是爲了遵守納斯達克的最低出價要求而實施的，經零星股票調整後，已發行股票的數量從約4,470萬股減少到約60萬股。拆分於2024年4月26日生效，普通股自該日開業之日起在拆分後的基礎上交易。該公司的普通股保留了其股票代碼 “ATXI”，並被分配了新的CUSIP編號。Avenue Therapeutics還在2024年4月24日的新聞稿中宣佈了反向股票拆分。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息